News Sort by Year All Years 2024 (12) 2023 (28) 2022 (31) 2021 (33) 2020 (37) 2019 (7) 2018 (4) Search June 26, 2024 TFF Pharmaceuticals Engages Outcome Capital As a Strategic Advisor for Evaluating Partnership and Licensing Opportunities June 24, 2024 TFF Pharmaceuticals Provides Regulatory Update on Tacrolimus Inhalation Powder (TFF TAC) Clinical Program for the Prevention of Lung Transplant Rejection May 23, 2024 TFF Pharmaceuticals and Leidos to Advance Next-Generation Biodefense Countermeasures Under the DARPA PPB Program into Preclinical Testing May 20, 2024 TFF Pharmaceuticals and Cleveland Clinic to Advance Multivalent Universal Influenza Vaccine Candidates into Preclinical Testing May 15, 2024 TFF Pharmaceuticals Provides Update on Tacrolimus Inhalation Powder (TFF TAC) Phase 2 Trial for the Prevention of Lung Transplant Rejection May 14, 2024 TFF Pharmaceuticals Reports First Quarter Financial Results and Provides Corporate Update May 1, 2024 TFF Pharmaceuticals Announces Closing of Pricing of $4.8 Million Public Offering April 29, 2024 TFF Pharmaceuticals Makes Available Phase 2 Data from Tacrolimus Inhalation Powder (TFF TAC) for the Prevention of Lung Transplant Rejection Presented at the Recent ISHLT Annual Meeting April 29, 2024 TFF Pharmaceuticals Announces Pricing of $4.8 Million Public Offering April 15, 2024 TFF Pharmaceuticals Announces Additional Positive Data from the Tacrolimus Inhalation Powder (TFF TAC) Phase 2 Trial Following Oral Presentation at the ISHLT 44th Annual Late Breaking Clinical Science Abstract Sessions